Fresh analysis indicates that individuals who discontinue new GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle programs.
Findings released in a major health publication demonstrates that while overweight individuals can lose about a fifth of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Users buying such treatments must be aware of the danger of rapid rebound weight gain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a reversion to original mass within about one and a half years.
Weighing Approaches
The research, which examined dozens of studies involving over 9,000 of patients, compared the outcomes of these new drugs with other pills.
Researchers note that individuals who shed pounds through dieting typically see a slower weight regain—perhaps 0.1 kg a month—after stopping.
Understanding the Fast Regain
Doctors believe the mechanism of the jabs accounts for the accelerated weight return.
These medications imitate a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels far above than normal may cause the body to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' leads to hunger is no longer kept in check, making excessive eating far more likely."
An Ongoing Issue?
Health authorities advise the jabs for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts argue that, given the high risk of relapse, the therapy might need to be life-long.
This opinion is reinforced by drug manufacturers, who say that the results "highlight the chronic character of obesity," akin to managing diseases like diabetes.
User Testimonies
Individuals who have discontinued the jabs explain a intense resurgence of hunger.
"I experienced a trigger flipping and you become extremely hungry," described one woman.
This challenge is compounded if patients have not established sustainable lifestyle or habit modifications during treatment.
Growing Interest
Survey data show that millions of people in the UK have tried these injections in the past year, with interest continuing to grow.
- Use is higher among women compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic solution and lasting health benefits likely depends on integrated behavioural management.
